#China #Shanghai #Immunotherapy #Lung Cancer #Jiahui Center

Immunotherapy Breakthrough at Jiahui Center

In a remarkable medical achievement, the Jiahui International Cancer Center (JICC) in Shanghai has successfully stabilized a 70-year-old US patient afflicted with advanced non-small cell lung cancer (NSCLC), alongside Parkinson's disease. The innovative treatment employed in this case was Ivonescimab, a novel immunotherapy currently only available in China.

This patient previously underwent all standard treatments available at MD Anderson Cancer Center in the United States without success. His medical team, confronted with the limited options, recommended Ivonescimab, which is notably the first bispecific PD-1/VEGF antibody approved for use in solid tumors. Following a video consultation at the end of November, the family decided to seek treatment at JICC, given its multidisciplinary expertise and the credentials of Dr. Xuan Linli, the Chief of Medical Oncology, who received training in the United States.

As part of the treatment process, the patient experienced immune-related complications that required intensive care. The JICC staff adeptly coordinated efforts among various specialists in oncology, neurology, and critical care, with the treatment supervised by Dr. Zhou Caicun, the lead researcher for Ivonescimab at the cancer center. Thankfully, the patient's condition has stabilized, and ongoing medical efforts are focused on controlling the disease's progression.

Jiahui International Cancer Center prides itself on providing seamless care pathways for international patients. From remote consultations and travel coordination to continuous updates for family members, the center offers a comprehensive healthcare experience. The patient’s daughter expressed profound gratitude towards the Jiahui team, especially to Nurse Cui, who provided daily care and emotional support, helping to uplift her father's spirits during a challenging time.

The success of this treatment showcases the potential of China's advancements in oncology, leading to new horizons for cancer patients globally. JICC is witnessing a growing interest and referrals from regions including North America, Europe, Asia, and the Middle East, positioning Shanghai as a center of excellence for cutting-edge cancer treatment functionalities.

Such achievements underline the importance of international collaboration in advancing cancer care, and the Jiahui International Cancer Center continues its mission to push boundaries in medical innovation, offering hope to those battling complex illnesses. For more updates on patient stories and treatment options, visit the official Jiahui website.